Literature DB >> 16990548

Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.

Yuval Shaked1, Alessia Ciarrocchi, Marcela Franco, Christina R Lee, Shan Man, Alison M Cheung, Daniel J Hicklin, David Chaplin, F Stuart Foster, Robert Benezra, Robert S Kerbel.   

Abstract

The contribution of bone marrow-derived circulating endothelial progenitor cells (CEPs) to tumor angiogenesis has been controversial, primarily because of their low numbers in blood vessels of untreated tumors. We show that treatment of tumor-bearing mice with vascular disrupting agents (VDAs) leads to an acute mobilization of CEPs, which home to the viable tumor rim that characteristically remains after such therapy. Disruption of this CEP spike by antiangiogenic drugs or by genetic manipulation resulted in marked reductions in tumor rim size and blood flow as well as enhanced VDA antitumor activity. These findings also provide a mechanistic rationale for the enhanced efficacy of VDAs when combined with antiangiogenic drugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16990548     DOI: 10.1126/science.1127592

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  205 in total

1.  Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma.

Authors:  Igor A Astsaturov; Neal J Meropol; R Katherine Alpaugh; Barbara A Burtness; Jonathan D Cheng; Sue McLaughlin; André Rogatko; Zhiheng Xu; James C Watson; Louis M Weiner; Steven J Cohen
Journal:  Am J Clin Oncol       Date:  2011-02       Impact factor: 2.339

2.  Circulation of progenitor cells in obese and lean colorectal cancer patients.

Authors:  Charles F Bellows; Yan Zhang; Jinyun Chen; Marsha L Frazier; Mikhail G Kolonin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-09-19       Impact factor: 4.254

Review 3.  Endothelial progenitor cells: current issues on characterization and challenging clinical applications.

Authors:  Thomas Resch; Andreas Pircher; Christian M Kähler; Johann Pratschke; Wolfgang Hilbe
Journal:  Stem Cell Rev Rep       Date:  2012-09       Impact factor: 5.739

4.  Increase in circulating endothelial progenitor cells predicts response in patients with advanced non-small-cell lung cancer.

Authors:  Yuichi Sakamori; Katsuhiro Masago; Katsuyuki Ohmori; Yosuke Togashi; Hiroki Nagai; Chiyuki Okuda; Young Hak Kim; Satoshi Ichiyama; Michiaki Mishima
Journal:  Cancer Sci       Date:  2012-04-15       Impact factor: 6.716

Review 5.  Targeting the vasculature of visceral tumors: novel insights and treatment perspectives.

Authors:  L V Klotz; M E Eichhorn; B Schwarz; H Seeliger; M K Angele; K-W Jauch; Christiane J Bruns
Journal:  Langenbecks Arch Surg       Date:  2012-03-14       Impact factor: 3.445

Review 6.  Circulating biomarkers in advanced renal cell carcinoma: clinical applications.

Authors:  Maria Hernandez-Yanez; John V Heymach; Amado J Zurita
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

7.  Cyclophosphamide enhances human tumor growth in nude rat xenografted tumor models.

Authors:  Yingjen Jeffrey Wu; Leslie L Muldoon; Dana Thomas Dickey; Seth J Lewin; Csanad G Varallyay; Edward A Neuwelt
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

Review 8.  Beyond chemotherapy: targeted therapies in ovarian cancer.

Authors:  Timothy A Yap; Craig P Carden; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

9.  Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization.

Authors:  Daniel J Nolan; Alessia Ciarrocchi; Albert S Mellick; Jaspreet S Jaggi; Kathryn Bambino; Sunita Gupta; Emily Heikamp; Michael R McDevitt; David A Scheinberg; Robert Benezra; Vivek Mittal
Journal:  Genes Dev       Date:  2007-06-15       Impact factor: 11.361

Review 10.  Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.

Authors:  Jie Ma; David J Waxman
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.